Investment Thesis — Humana Inc.
The market is mispricing Humana's deep discount, extrapolating current margin pressures as permanent rather than cyclical. We believe its robust revenue base and strategic adjustments position it for a significant re-rating once even modest profitability improvements become evident, making its current P/S and P/B multiples an extreme undervaluation.
Catalysts
- Positive Medicare Advantage rate announcement for 2025, signaling regulatory stability
- Evidence of successful cost-containment efforts leading to sequential improvement in net margins
- Strategic divestitures or partnerships that streamline operations and focus on higher-margin segments
Risk Factors
- Higher-than-expected medical utilization trends, particularly in Medicare Advantage
- Further unfavorable adjustments to Medicare Advantage reimbursement rates
- Increased competitive pressure in key markets, hindering pricing power
Key Debates
24% revenue growth proves unsustainable by Q4
Gross margin compresses 100bps by H2 2024
Fwd P/E contracts to 15x by FY24 due to margin risk